Erick Antonio Osorio-López1,2, Diana Vilar-Compte2, Jaquelyn García-Tirado1, Alexandra Martin-Onraet3. 1. Faculty of Medicine, National Autonomous University of Mexico (Universidad Nacional Autonoma de México), Mexico City, Mexico. 2. Department of Infectious Diseases, National Cancer Institute (Instituto Nacional de Cancerologia), Av. San Fernando 22, col. Sección XVI. 14000, Tlalpan Delegation, Mexico City, Mexico. 3. Department of Infectious Diseases, National Cancer Institute (Instituto Nacional de Cancerologia), Av. San Fernando 22, col. Sección XVI. 14000, Tlalpan Delegation, Mexico City, Mexico. alexitemaon@gmail.com.
Abstract
OBJECTIVE: To determine the prevalence of Latent Tuberculosis in patients with hematological neoplasms at the Instituto Nacional de Cancerología in Mexico City using the Tuberculin skin test (TST). METHODS: This retrospective study included all patients with a recent diagnosis of hematological neoplasms who were admitted for treatment from 2017 to 2018 and who were screened for latent tuberculosis with the TST. The prevalence of latent tuberculosis in this group, tolerance and therapeutic adherence in treated patients are described. RESULTS: The files of 446 patients with hematological malignancy who had a TST were reviewed. The prevalence of latent tuberculosis was 31.2% (n = 139). Ninety-three patients received isoniazid, 15.1% had some adverse reactions, but only 4 (4.3%) had to discontinue treatment. Two patients with latent tuberculosis under treatment with Isoniazid reactivated tuberculosis infection. CONCLUSIONS: The prevalence in our study was within the range of other similar Mexican populations. Isoniazid treatment had an adequate tolerance and adherence. Longer follow-up could offer more information on the risk of reactivation in both groups.
OBJECTIVE: To determine the prevalence of Latent Tuberculosis in patients with hematological neoplasms at the Instituto Nacional de Cancerología in Mexico City using the Tuberculin skin test (TST). METHODS: This retrospective study included all patients with a recent diagnosis of hematological neoplasms who were admitted for treatment from 2017 to 2018 and who were screened for latent tuberculosis with the TST. The prevalence of latent tuberculosis in this group, tolerance and therapeutic adherence in treated patients are described. RESULTS: The files of 446 patients with hematological malignancy who had a TST were reviewed. The prevalence of latent tuberculosis was 31.2% (n = 139). Ninety-three patients received isoniazid, 15.1% had some adverse reactions, but only 4 (4.3%) had to discontinue treatment. Two patients with latent tuberculosis under treatment with Isoniazid reactivated tuberculosis infection. CONCLUSIONS: The prevalence in our study was within the range of other similar Mexican populations. Isoniazid treatment had an adequate tolerance and adherence. Longer follow-up could offer more information on the risk of reactivation in both groups.
Entities:
Keywords:
Hematologic malignancies; Latent tuberculosis; Tuberculin skin test
Authors: Jorge A Barrios-Payán; Mauricio Castañón-Arreola; Mario A Flores-Valdez; Rogelio Hernández-Pando Journal: Salud Publica Mex Date: 2010 Jan-Feb
Authors: Leila C Kahwati; Cynthia Feltner; Michael Halpern; Carol L Woodell; Erin Boland; Halle R Amick; Rachel Palmieri Weber; Daniel E Jonas Journal: JAMA Date: 2016-09-06 Impact factor: 56.272
Authors: A L Kritski; M J Marques; M F Rabahi; M A Vieira; E Werneck-Barroso; C E Carvalho; G de N Andrade; R Bravo-de-Souza; L M Andrade; P P Gontijo; L W Riley Journal: Am J Respir Crit Care Med Date: 1996-01 Impact factor: 21.405
Authors: Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap Journal: MMWR Recomm Rep Date: 2020-02-14